China’s HCV Drug Market To Grow To $150 Million By 2012
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's hepatitis C virus drug market will grow to $150 million by 2012, according to a report released in September by Decision Resources
You may also be interested in...
Amgen Expands Hep C Agreement With Three Rivers To China
SHANGHAI - Three Rivers Pharmaceuticals has signed a definitive licensing agreement with Amgen to acquire further commercial rights, including China, for the hepatitis C drug Infergen, the company announced Sept. 1
Amgen Expands Hep C Agreement With Three Rivers To China
SHANGHAI - Three Rivers Pharmaceuticals has signed a definitive licensing agreement with Amgen to acquire further commercial rights, including China, for the hepatitis C drug Infergen, the company announced Sept. 1
Genelabs, Taiwan National Health Research Institutes and Genovate To Co-Develop New Hepatitis C Treatment
SHANGHAI - Genelabs Technologies inked a development agreement with the Taiwan National Health Research Institutes and Genovate Biotechnology to co-develop drugs to treat hepatitis C, the company announced July 23